Zentalis Pharmaceuticals (ZNTL) Change in Accured Expenses (2019 - 2026)

Zentalis Pharmaceuticals has reported Change in Accured Expenses for 8 years, with the latest figure at -$1.5 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 63.93% year-over-year to -$1.5 million; the trailing twelve-month figure through Mar 2026 stood at -$14.7 million (down 116.95% YoY), and the FY2025 full-year result was -$17.3 million, up 3.92% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$1.5 million, down from -$733000.0 in the prior quarter.
• The five-year high for Change in Accured Expenses was $11.8 million in Q2 2024, with the low at -$15.2 million in Q1 2024.
• Average Change in Accured Expenses over 5 years is -$608411.8, with a median of -$1.4 million recorded in 2023.
• Peak annual rise in Change in Accured Expenses reached 368.48% in 2024, while the deepest fall reached 980.72% in 2024.
• Tracing ZNTL's Change in Accured Expenses over 5 years: stood at $5.0 million in 2022, then surged by 105.88% to $10.4 million in 2023, then plunged by 124.64% to -$2.6 million in 2024, then soared by 71.39% to -$733000.0 in 2025, then tumbled by 97.95% to -$1.5 million in 2026.
• The last three Change in Accured Expenses figures came in at -$1.5 million (Q1 2026), -$733000.0 (Q4 2025), and -$2.0 million (Q3 2025), per Business Quant data.

Peer Comparison